Uveitis Gene-Expression Profiling
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00874471 |
Recruitment Status :
Completed
First Posted : April 2, 2009
Last Update Posted : April 9, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:
- Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis
- Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's
- Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits
- Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.
The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.
Condition or disease |
---|
Uveitis |
Study Type : | Observational |
Actual Enrollment : | 280 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Study Start Date : | June 2005 |
Actual Primary Completion Date : | July 2010 |

Group/Cohort |
---|
sarcoidosis |
ankylosing spondylitis |
Behcet's disease |
toxoplasmosis |
herpetic acute retinal necrosis |
idiopathic uveitis |
ankylosing spondylitis (no uveitis) |
sarcoidosis (no uveitis) |
Behcet's disease (no uveitis) |
normal control |
- Correlation of blood transcriptome with form of uveitis [ Time Frame: time of office visit for disease evaluation ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:
- ankylosing spondylitis
- sarcoidosis
- Behçet's disease
- toxoplasmosis
- herpetic acute retinal necrosis; AND
- idiopathic uveitis
-
Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:
- ankylosing spondylitis
- sarcoidosis; AND
- Behçet's disease
- The study group will also include 30 normal control volunteers aged 21 years or older.
Exclusion Criteria:
- Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00874471
United States, Oregon | |
Oregon Health & Science University | |
Portland, Oregon, United States, 97239-3098 |
Principal Investigator: | James Rosenbaum, MD | Oregon Health and Science University |
Responsible Party: | Jim Rosenbaum, Professor, Oregon Health and Science University |
ClinicalTrials.gov Identifier: | NCT00874471 History of Changes |
Other Study ID Numbers: |
R01EY015858 ( U.S. NIH Grant/Contract ) |
First Posted: | April 2, 2009 Key Record Dates |
Last Update Posted: | April 9, 2014 |
Last Verified: | April 2014 |
Uveitis Uveal Diseases Eye Diseases |